Spotlight On... Consent decree issued against recalcitrant compounder; Aurobindo to build plant in Saudi Arabia; U.K.'s Cell Therapy Catapult works on viral vector manufacturing; and more...

The FDA has secured a consent decree against a Texas compounder that had questioned FDA authority over its operations. The FDA says that a federal judge issued the consent decree last week against Downing Labs of Dallas, co-owners Ashley Michelle Downing and Christopher Van Downing, and pharmacist-in-charge Roger Mansfield. Downing Labs, formerly known as NuVision Pharmacy, had continued to manufacture adulterated drugs even after repeated warnings from the FDA, the regulator said. The compounder, which had resisted FDA pressure to recall all of its sterile drugs, finally relented last fall. Release | More

> Saudi Arabia, which has been recruiting companies to open drug manufacturing facilities, says India's Aurobindo will the next to build a plant there. Release

> The Cell Therapy Catapult in England said that it is working with Synpromics on a project it hopes will speed viral vector manufacturing for the development of cell and gene therapy drug production. Report

> Eagle Pharmaceuticals says it will work with CMO AMRI ($AMRI) to develop and manufacture several complex parenteral drug products for the U.S. market. Report

Suggested Articles

The FDA asked five drugmakers to pull their version of extended-release metformin off U.S. shelves after finding carcinogen contamination.

The FDA backtracked on its earlier testing and found NDMA contamination in the extended release formulation of certain generic versions of metformin.

GSK has formed several collaborations across the globe that will use its AS03 adjuvant to develop vaccines against the novel coronavirus.